89241-94-1

Basic information

• Product Name: 2-Pyridinecarboxylic acid, 3-amino-4-cyano-, ethyl ester
• Synonyms: 2-Pyridinecarboxylic acid,3-amino-4-cyano-,ethyl ester
• CAS NO: 89241-94-1
• Molecular Formula: C9H9N3O2
• Molecular Weight: 191.189
• Mol File: 89241-94-1.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 383.1±42.0 °C(Predicted)
• Density: 1.28±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 2-Pyridinecarboxylic acid, 3-amino-4-cyano-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Pyridinecarboxylic acid, 3-amino-4-cyano-, ethyl ester(89241-94-1)
• EPA Substance Registry System: 2-Pyridinecarboxylic acid, 3-amino-4-cyano-, ethyl ester(89241-94-1)

Safety Data

• Hazardous Substances Data: 89241-94-1(Hazardous Substances Data)

Upstream product

• 1759-25-7 ethyl 2-cyano-2-(formyl-amino)acetate 
• 107-13-1 acrylonitrile 
• 76-05-1 trifluoroacetic acid 
• 32683-02-6 ethyl-2-aminocyano acetate 
• 3849-21-6 ethyl cyanoglyoxylate-2-oxime 

Downstream Products

• 155879-89-3 3-amino-4-cyanopyridine-2-carboxamide 

Relevant articles and documents

COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF

The present invention provides KDM5 inhibitor. The compound disclosed herein represented by the general formula (Z): wherein all symbols have the same meanings as the definitions described in the specification; or a salt thereof is useful as a prophylactic and/or therapeutic agent for cancer, Huntington's disease, or Alzheimer's disease and the like.

PYRIDOPYRIMIDINONE ANTIANGINAL AGENTS

Compounds of the formula and pharmaceutically acceptable salts thereof, wherein R 1 is H, C 1 -C 4 alkyl CN or CONR 4 R 5 ; R 2 is C 2 -C 4 alkyl; R 3 is SO 2 NR 6 R 7, NO 2, NH 2, NHCOR 8 NHSO 2 R 8 or N(SO 2 R 8) 2 ; R 4 and R 5 are each independently selected from H and C 1 -C 4 alkyl; R 6 and R 7 are each independently selected from H and C 1 -C 4 alkyl optionally substituted with CO 2 R 9, OH, pyridyl 5-isoxazolin-3-onyl, morpholino or 1-imidazolidin-2-onyl; or together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino, morpholino, 1-pyrazolyl or 4-(NR 10)-1-piperazinyl group wherein any of said groups may optionally be substituted with one or two substituents selected from C 1 -C 4 alkyl, CO 2 R 9, NH 2 and OH; R 8 is C 1 -C 4 alkyl or pyridyl; R 9 is H or C 1 -C 4 alkyl; and R 10 is H, C 1 -C 4 alkyl or (hydroxy) C 2 -C 3 alkyl; are selected cGMP PDE inhibitors useful in the treatment of, inter alia, cardiovascular disorders such as angina, hypertension, heart failure and atherosclerosis